(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have previously undergone endocrine therapy. … Read the full press release →
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Breast Cancer Patients, Daiichi Sankyo, HER2-Low, Ken Takeshita, partnership, Pre-Chemotherapy, safety, Susan Galbraith, sustainability, Ultralow